Squamous Cell Carcinoma of Head and Neck Clinical Trial
Official title:
A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10).
| Verified date | May 2024 |
| Source | Merck Sharp & Dohme LLC |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first-line treatment in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). No statistical hypothesis will be tested in this study.
| Status | Active, not recruiting |
| Enrollment | 101 |
| Est. completion date | July 25, 2024 |
| Est. primary completion date | February 20, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Has histologically or cytologically-confirmed diagnosis of R/M HNSCC that is considered incurable by local therapies - Male participants refrain from donating sperm plus are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 95 days after carboplatin/paclitaxel - Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) or use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after pembrolizumab or 30 days after paclitaxel or 6 months after carboplatin whichever occurs last, and agree not to donate or freeze eggs during this period - Has adequate organ function Exclusion Criteria: - Has disease that is suitable for local therapy administered with curative intent - Has a life expectancy of less than 3 months and/or has rapidly progressive disease - Has a diagnosed and/or treated additional malignancy within 5 years prior to allocation with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, curatively resected in situ cervical cancer and curatively resected in situ breast cancer - Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis - Has a history of or current non-infectious pneumonitis/interstitial lung disease that requires steroids - Has an active infection requiring systemic therapy - Has a known history of human immunodeficiency virus (HIV) infection - Has a known history of Hepatitis B or Hepatitis C virus infection - Has had an allogenic tissue/solid organ transplant |
| Country | Name | City | State |
|---|---|---|---|
| Argentina | Fundación Respirar ( Site 0306) | Buenos Aires | |
| Argentina | IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0303) | Buenos Aires | |
| Argentina | Instituto Medico Especializado Alexander Fleming ( Site 0301) | Buenos Aires | |
| Argentina | Hospital Provincial del Centenario ( Site 0304) | Rosario | Santa Fe |
| Argentina | Centro Medico San Roque ( Site 0302) | San Miguel de Tucuman | Tucuman |
| Australia | The Townsville Hospital ( Site 0105) | Douglas | Queensland |
| Australia | St Vincents Hospital Melbourne ( Site 0101) | Fitzroy | Victoria |
| Australia | Orange Health Services ( Site 0106) | Orange | New South Wales |
| Australia | Gold Coast University Hospital ( Site 0103) | Southport | Queensland |
| Brazil | CETUS Hospital Dia Oncologia ( Site 0400) | Belo Horizonte | Minas Gerais |
| Brazil | Centro Regional Integrado de Oncologia ( Site 0403) | Fortaleza | Ceara |
| Brazil | ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0406) | Ijui | Rio Grande Do Sul |
| Brazil | Liga Norte Riograndense Contra o Cancer ( Site 0404) | Natal | Rio Grande Do Norte |
| Brazil | A.C. Camargo Cancer Center ( Site 0405) | Sao Paulo | |
| Brazil | Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0402) | Sao Paulo | |
| Brazil | Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0401) | Sao Paulo | |
| Canada | Tom Baker Cancer Center ( Site 0014) | Calgary | Alberta |
| Canada | Cancer Centre of Southeastern Ontario at Kingston General Hospital ( Site 0004) | Kingston | Ontario |
| Canada | Dr. H. Bliss Murphy Cancer Centre ( Site 0001) | Saint John S | Newfoundland and Labrador |
| Canada | CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0003) | Sherbrooke | Quebec |
| Canada | Princess Margaret Cancer Centre ( Site 0005) | Toronto | Ontario |
| United States | Erie County Medical Center-Head & Neck Surgery and Plastic & Reconstructive Surgery ( Site 0268) | Buffalo | New York |
| United States | Charleston Oncology ( Site 0231) | Charleston | South Carolina |
| United States | Novant Health Presbyterian ( Site 0261) | Charlotte | North Carolina |
| United States | Baptist MD Anderson Cancer Center ( Site 0215) | Jacksonville | Florida |
| United States | Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0262) | Mineola | New York |
| United States | Yale-New Haven Hospital-Yale Cancer Center ( Site 0265) | New Haven | Connecticut |
| United States | Helen F. Graham Cancer Center & Research Institute ( Site 0214) | Newark | Delaware |
| United States | Orlando Health, Inc. ( Site 0216) | Orlando | Florida |
| United States | UPMC Hillman Cancer Center ( Site 0253) | Pittsburgh | Pennsylvania |
| United States | Virginia Commonwealth University ( Site 0233) | Richmond | Virginia |
| United States | Washington University School of Medicine ( Site 0240) | Saint Louis | Missouri |
| United States | Regions Hospital ( Site 0227) | Saint Paul | Minnesota |
| United States | Abington Hospital - Asplundh Cancer Center ( Site 0229) | Willow Grove | Pennsylvania |
| United States | Novant Health Forsyth Medical Center ( Site 0266) | Winston-Salem | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| Merck Sharp & Dohme LLC |
United States, Argentina, Australia, Brazil, Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Objective Response Rate (ORR) | ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) per Response Evaluation Criteria in Solid Tumors Update and Clarification 1.1 (RECIST 1.1) which was adjusted for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. | Up to ~25 months | |
| Secondary | Duration of Response (DOR) | For participants who demonstrated a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurred first. RECIST 1.1 was adjusted for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The DOR as assessed by blinded independent central review based on RECIST 1.1 was presented. | Up to ~25 months | |
| Secondary | Progression-free Survival (PFS) | PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of =5 mm. The appearance of one or more new lesions was also considered PD. RECIST 1.1 was been adjusted for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. PFS as assessed by blinded independent central review based on RECIST 1.1 was from product-limit (Kaplan-Meier) method for censored data. | Up to ~25 months | |
| Secondary | Overall Survival (OS) | OS was defined as the time from first dose of study treatment to death due to any cause. PFS as assessed by blinded independent central review based on RECIST 1.1 was from product-limit (Kaplan-Meier) method for censored data. | Up to ~25 months | |
| Secondary | Percentage of Participants Who Experience an Adverse Event (AE) | An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced an AE was reported. | Up to ~25 months | |
| Secondary | Percentage of Participants Who Discontinued Study Treatment Due to an AE | An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study treatment due to an AE was reported. | Up to ~25 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02537223 -
Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer
|
Phase 1 | |
| Completed |
NCT00824343 -
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
|
Phase 2 | |
| Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05366166 -
Pembrolizumab Plus Olaparib in LA-HNSCC
|
Phase 2 | |
| Terminated |
NCT04502888 -
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
|
Phase 1 | |
| Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
| Completed |
NCT04098458 -
Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC
|
N/A | |
| Not yet recruiting |
NCT04528420 -
Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer
|
N/A | |
| Active, not recruiting |
NCT03997968 -
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05061420 -
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
|
Phase 2 | |
| Completed |
NCT04939480 -
Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN
|
Phase 2 | |
| Recruiting |
NCT04260802 -
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04465487 -
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT05845307 -
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
|
Early Phase 1 | |
| Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
| Completed |
NCT04601402 -
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
|
Phase 1 | |
| Completed |
NCT00756444 -
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Withdrawn |
NCT04129320 -
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
|
Phase 2/Phase 3 |